2021
Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype
Han H, . T, Yu J, Golshan M, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Dai M, Liao G. Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype. Journal Of Cancer Science And Clinical Therapeutics 2021, 05 DOI: 10.26502/jcsct.5079127.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancer subtypesSurvival benefitBreast cancerCancer subtypesPatientsSurgeryCancerSubtypes
2015
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? European Journal Of Surgical Oncology 2015, 41: 1288-1292. PMID: 26238477, DOI: 10.1016/j.ejso.2015.07.013.Peer-Reviewed Original ResearchConceptsDe novo metastatic breast cancerNovo metastatic breast cancerMetastatic breast cancerBreast cancer patientsBreast cancerSurvival benefitCancer patientsPrimary tumorRetrospective non-randomized clinical studyDe novo metastatic diseasePrimary metastatic breast cancerNon-randomized clinical studyTumor-related symptomsPrimary tumor excisionSelection of patientsWound issuesBiologic therapyMetastatic diseaseSystemic therapyDistant metastasisEpidemiological burdenInitial diagnosisSurgical excisionPatient preferencesTumor excision
2009
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan P, Tung N, Isakoff S, Golshan M, Richardson A, Corben A, Smith B, Gelman R, Winer E, Garber J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Journal Of Clinical Oncology 2009, 27: 551-551. DOI: 10.1200/jco.2009.27.15_suppl.551.Peer-Reviewed Original ResearchTriple-negative breast cancerClinical partial responseClinical complete responseNeoadjuvant cisplatinNeoadjuvant therapyPulmonary embolismBreast cancerStable diseaseProgressive diseasePathological responseHearing lossWeeks x 4 cyclesTreatment of TNBCSingle-arm phase II trialArm phase II trialCycles of bevacizumabEfficacy of bevacizumabGrade 4 toxicityComplete pathological responseAddition of bevacizumabPhase II trialMetastatic breast cancerEfficacy of chemotherapyNegative breast cancerTissue-based assays